FDA Approves Mirum and Incyte's Atebrioz for Rare Bone Disease Treatment

Key Facts

The FDA approved Atebrioz, developed by Mirum Pharmaceuticals and Incyte, for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). Benzinga reported that the approval covers patients aged 12 and older, with the therapy designed to reduce abnormal bone formation characteristic of this rare condition.

MIRM closed at $89.70 on September 25, 2026, while INCY closed at $123.89 on the same date. This regulatory milestone positions the drug as a competitor to existing treatments and establishes a new revenue stream for both biotechnology firms in the specialized medicine market.